Company: HCWB
Filing Date: 2025-02-26
Form Type: DEFR14A
Source: 0001193125-25-035319
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-02-26
Form: DEFR14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 AMENDMENT NO. 1 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☒ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

HCW BIOLOGICS INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act 
 Rules 14a-6(i)(1) and 0-11.                                              |

EXPLANATORY NOTE On February 21, 2025, HCW Biologics Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission its Definitive Proxy Statement on Schedule 14A for its Special Meeting of Stockholders (the “Proxy Statement”) to be held on March 31, 2025 (the “Special Meeting”). This Amendment No. 1 to the Proxy Statement (“Amendment No. 1”) is filed solely to amend the Proxy Statement to correct, in two places in the Proxy Statement, an inadvertent clerical error to the number of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) outstanding as of the close of business on February 18, 2025, the record date for the Special Meeting, from 44,540,394 shares of Common Stock to 44,544,996 shares of Common Stock. This Amendment No. 1 supersedes in its entirety only (1) the disclosure on page 3 of the Proxy Statement answering the following question: “Q: Who may vote at the Special Meeting”, and (2) the table on page 13 of the Proxy Statement showing the impact of a Reverse Stock Split at